Faculty

Dr. Andrew J. Cutler attended Haverford College in Philadelphia, Pennsylvania, earning a BS in Biology.  He received his MD from the University of Virginia School of Medicine, where he was also elected to the Alpha Omega Alpha (AOA) honor medical society and received the Merck Award for outstanding medical scholarship. He completed his medical internship, Internal Medicine residency and Psychiatry residency at the University of Virginia Medical Center, where he served as Chief Resident of Psychiatric Medicine and did research on dopamine receptor pharmacology in the lab of James P. Bennett, MD, PhD.  Dr. Cutler then served as the first Assistant Professor and Director of Psychiatric Medicine at the University of Chicago.  He has been Board Certified in both Internal Medicine and Psychiatry.

Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials.  

Dr. Cutler has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings.  He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards.  He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations.  He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences.

Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society, and the American Medical Association.  He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media.

Dr. Laxman B. Bahroo is an assistant professor and co-director of the Neurology Residency Program at MedStar Georgetown University Hospital. He attended medical school in New Jersey, and he completed an internship at Saint Luke's Hospital in Bethlehem, Pa. Dr. Bahroo completed his neurology residency as served as the Academic Chief Resident in his final year at MedStar Georgetown University Hospital. He also completed a two-year fellowship in movement disorders at MedStar Georgetown University Hospital. As a board-certified neurologist and member of the Movement Disorders program, his primary areas of focus in movement disorders include the medical and surgical management of Parkinson's disease and essential tremor. He also specializes in therapeutic botulinum toxin injections for dystonia spasticity and excessive drooling.

Dr. Robin Carhart-Harris is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry and Director of Neuroscape’s Psychedelics Division at the University of California, San Francisco. He moved to Imperial College London in 2008 after obtaining a PhD in psychopharmacology from the University of Bristol. Robin has designed human brain imaging studies with LSD, psilocybin, MDMA, and DMT, and two clinical trials of psilocybin for depression. He has authored over 127 papers. Robin founded the Centre for Psychedelic Research at Imperial College London in 2019, and in 2021, was named in TIME magazine’s "100 Next" – a list of 100 rising stars shaping the future.

Dr. Leslie Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. He is the Editor-in-Chief of the International Journal of Clinical Practice, published by Wiley. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and after nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and interpretation.

Dr. Citrome is a member of the Board of Directors of the American Society of Clinical Psychopharmacology. Main areas of interest include schizophrenia, bipolar disorder, and major depressive disorder. He is a frequent lecturer on the quantitative assessment of clinical trial results using the evidence-based medicine metrics of number needed to treat and number needed to harm.

Dr. Citrome is the author or co-author of over 400 research reports, reviews, and chapters in the scientific literature, is on the editorial board of 13 different medical journals, reviews for over 90 journals, and has lectured extensively throughout the USA, Canada, Europe, and Asia.

Dr. Karl Doghramji is Professor of Psychiatry, Neurology, and Medicine at Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, Pennsylvania, and Medical Director of the Jefferson Sleep Disorders Center at Thomas Jefferson University Hospital, also in Philadelphia. Dr Doghramji is also Program Director of the Fellowship in Sleep Medicine.

Dr. Doghramji works as a clinician, researcher, educator, and physician leader, and has a national clinical and academic reputation in sleep medicine and biological psychiatry. He is actively engaged in interdisciplinary care with academic contributions in the fields of psychiatry and sleep medicine. He has received multiple grants and authored numerous academic publications. He is a frequent presenter at national and international scientific sessions, symposia, and courses.

Dr. Doghramji has held numerous positions with the American Academy of Sleep Medicine. He was elected Fellow of the American Academy of Sleep Medicine; in 1994, he was elected to the American College of Psychiatrists; and, in 2017, was elected Distinguished Life Fellow of the American Psychiatric Association. He has been selected by Philadelphia Magazine for the list of "Top Doctors."

Dr. Doghramji received his medical degree from Jefferson Medical College and post graduate training at Presbyterian-University of Pennsylvania Medical Center in Philadelphia and Thomas Jefferson University. He completed a fellowship in sleep medicine at Albert Einstein School of Medicine in New York. He is also an Academic Associate in the Adult Division of the Institute of the Psychoanalytic Center of Philadelphia.

Dr. Joseph Goldberg is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient.

Dr. Goldberg has published over 180 original research publications in major psychiatric journals as well as 3 books on topics related to mood disorders, focusing on the use of anticonvulsant mood stabilizers and atypical antipsychotics, safety risks with antidepressants in bipolar disorder, management of drug side effects, features related to rapid cycling bipolar disorder, suicide risk in bipolar disorder, cognitive dysfunction in bipolar disorder, pharmacogenetics in bipolar disorder, comorbid psychiatric disorders in bipolar disorder, and the long-term functional course and outcome of bipolar disorder and depression. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences, such as the American Psychiatric Association, the Society of Biological Psychiatry, the American Society for Clinical Psychopharmacology, the American College of Neuropsychopharmacology, the European College of Neuropsychopharmacology, the Collegium Internationale Neuropsychopharmacologicum, the International Society for Affective Disorders, and the International Society for Bipolar Disorders.

Dr. David W. Goodman is an assistant professor in the department of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore, and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD. His interests include adult ADHD, associated mood/anxiety/substance use disorders, and complex psychopharmacology.

Ms. Amber Hoberg received her Master’s degree from the University of Texas Health Science Center in San Antonio, Texas. She completed clinical internship training at Alamo Mental Health Group, Laurel Ridge Treatment Center, Genesis Psychiatric Center, and La Paz Mental Health Center in San Antonio.

Ms. Hoberg is recognized as an Advanced Practice Nurse and as a Registered Nurse by the State of Texas and is certified as an Advanced Practice Nurse by the American Nurses Credentialing Center. Amber's areas of special interest are medication management, intellectually disabled, adult and geriatric mental health care.

Dr. Vladimir Maletic is a clinical professor of psychiatry and behavioral science at the University of South Carolina School of Medicine in Greenville, and a consulting associate in the Division of Child and Adolescent Psychiatry, Department of Psychiatry, at Duke University in Durham, North Carolina. Dr. Maletic received his medical degree in 1981 and his master’s degree in neurobiology in 1985, both from the University of Belgrade in Yugoslavia. He went on to complete a residency in psychiatry at the Medical College of Wisconsin in Milwaukee, followed by a residency in child and adolescent psychiatry at Duke University.

Dr. Maletic is a member of several professional organizations, including the Southern Psychiatric Association and The American College of Psychiatrists. He has published three books, including “The New Mind-Body Science of Depression”, numerous articles and several book chapters. Dr. Maletic has participated in various national and international meetings and congresses. His special areas of interest include the neurobiology of mood disorders, schizophrenia, pain, and the regulation of sleep and wakefulness. Dr. Maletic is board certified in psychiatry and neurology. 

Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.   

Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.   

Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.   

Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.  

Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.  

Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.  

Dr. Jonathan M. Meyer is a graduate of Stanford University and Harvard Medical School and finished his adult psychiatry residency at Los Angeles County-USC Medical Center. At LA County-USC he subsequently completed fellowships in Consultation/Liaison Psychiatry and Psychopharmacology Research.

In addition to teaching duties at UC San Diego, Dr. Meyer has performed extensive research on the metabolic effects of antipsychotics, and the impact of antipsychotic medications on glucose-insulin homeostasis. Dr. Meyer has published numerous articles and book chapters on various aspects of antipsychotic psychopharmacology including the pharmacokinetics of oral and depot antipsychotics, metabolic effects of atypical antipsychotics, as well as on the health care outcomes in patients with severe mental illness.

Dr. Meyer is a national speaker about side effects and metabolic issues surrounding antipsychotic therapy, is chief editor of Medical Illness and Schizophrenia, now in its 2nd edition, and is the sole author of the chapter on the “Pharmacotherapy of Psychosis and Mania” in the last two editions of Goodman & Gilman's The Pharmacological Basis of Therapeutics.

Dr. Thomas L. Schwartz is active on many teaching, administrative and curriculum committees at SUNY, he also provides direct resident supervision, lectures in several courses, and directs and organizes continuing medical education events for the psychiatry department.

Dr. Schwartz received his medical degree from and completed his residency in adult psychiatry at the State University of New York (SUNY) Upstate Medical University in Syracuse, New York.

Dr. Schwartz’s abilities as a medical educator have been recognized with the Marc H. Hollander, MD, Psychiatry Award, Teacher of the Year, and Mentor of the Year awards from SUNY Upstate Medical University, Nancy Roeske, MD, Irma Bland, Certificates of Recognition for Excellence in Medical Student and Resident Education from the American Psychiatric Association, the SUNY Upstate President’s and the SUNY Chancellor’s Award for Teaching.

Dr. Schwartz is the author of Practical Psychopharmacology: Basic to Advanced Principles, "Stahl’s Essential Psychopharmacology” Case Studies Volume 2, Integrating Psychotherapy and Pharmacotherapy, Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention, Second and Third Generation Antipsychotics.  He is the editor of Depression: Treatment Strategies and Management, 1st and 2nd Eds. and is the Deputy Editor for the journal CNS Spectrums.

Dr. Manpreet K. Singh is Associate Professor of Psychiatry and Behavioral Sciences, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders.

Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009.

Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes.

In her spare time, Dr. Singh enjoys traveling and hiking with her husband and three children, and avidly teaches Indian classical music.

Dr. Stephen M. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago, as a member of the Honors Program in Medical Education, and his Ph.D. degree in pharmacology and physiology from the University of Chicago. Dr. Stahl has trained in three specialties: internal medicine at the University of Chicago; neurology at the University of California in San Francisco; and psychiatry at Stanford University. He is board certified in psychiatry. 

Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles (UCLA), the Institute of Psychiatry London, the Institute of Neurology London, and, currently, as professor at the University of California at San Diego (UCSD) and as an Honorary Visiting Senior Fellow in the Department of Psychiatry at the University of Cambridge in the UK. He also directs psychopharmacology services and academic programs for the eight-facility, 6500 patient California Department of State Hospital System, where he also heads their assessment and treatment efforts to reduce violence. Dr. Stahl was formerly Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the internet and teaching how to teach.     

Dr. Stahl currently serves as editor-in-chief of CNS Spectrums. He is also past associate editor of Acta Psychiatrica Scandinavica, former clinical field editor for the International Journal of Neuropsychopharmacology and is currently on numerous editorial boards of other leading journals including the ACNP’s journal Neuropsychopharmacology. He has conducted numerous research projects during his career awarded by the National Institute of Mental Health (NIMH), by the Department of Veteran Affairs (VA) and by the pharmaceutical industry. Author of over 500 articles and chapters, and more than 1600 scientific presentations and abstracts, Dr. Stahl is an internationally renowned clinician, researcher, and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has written 35 books and edited 12 others, including the best-selling and award-winning textbook, Stahl’s Essential Psychopharmacology, now in its fifth edition, the best-selling and award-winning clinical manual, Essential Psychopharmacology Prescriber’s Guide, now in its sixth edition. 

Lectures, courses, and preceptorships based upon his textbooks have taken him to dozens of countries on 6 continents to speak to tens of thousands of physicians, mental health professionals and students at all levels. His lectures and scientific presentations have been distributed as more than a million CD-ROMs, internet educational programs, videotapes, audiotapes, and programmed home study texts for continuing medical education to hundreds of thousands of professionals in many different languages. His courses and award-winning multimedia teaching materials are used by psychopharmacology teachers and students throughout the world.   

Dr. Stahl serves as a fellow of the ACNP (American College of Neuro-psychopharmacology), of the British Association of Psychopharmacology (BAP) and of the CINP, where he was formerly vice president and is a Distinguished Life Fellow of the American Psychiatric Association (APA). He also has served on numerous medical and scientific advisory boards for the pharmaceutical industry, for the biotechnology and medical information industry, and for various nonprofit and public service organizations, including appointment by the State of California and past Chair of the Medi-Cal Oversight Board for Medicines (Drug Utilization Review Board).   

His educational research programs are monitoring changes in diagnosing and prescribing behaviors as outcomes from various educational interventions for programs organized by the Neuroscience Education Institute, which he chairs. He also has an active clinical practice specializing in psychopharmacologic treatment of resistant cases.   

He has been awarded the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education for his contributions to postgraduate education in psychiatry and neurology. His books have won the British Medical Association’s Book of the Year Award and Arbor Scientia has been awarded the business of the year award from the local chamber of commerce. Dr. Stahl is also the winner of the A.E. Bennett Award of the Society of Biological Psychiatry, the APA/San Diego Psychiatric Society Education Award, the UCSD department of psychiatry residency teaching award, and has been cited as both one of “America’s Top Psychiatrists” and one of the “Best Doctors in America.” He was honored with the Distinguished Psychiatrist Award of the APA and gave the Distinguished Psychiatrist Lecture for 2013. Recently, his alma mater Northwestern University honored him by naming their annual award for the best medical student going into psychiatry the Stephen Stahl award. Dr. Stahl was named the 2016 David A Mrazek Memorial Award Winner by the American Psychiatric Association and delivered the Mrazek Lecture at the annual meeting of the APA.

Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry, and neuroanatomy of anxiety disorders in children and adolescents. His examination of cortical thickness in adolescents with anxiety, revealed abnormalities in cortical thickness in an ensemble of regions responsible for fear learning, fear extinction, reflective functioning (e.g., mentalization), and regulation of the amygdala. Additionally, gray matter volumes in youth with anxiety disorders are greater in the dorsal anterior cingulate and decreased in the ventrolateral prefrontal cortex), cuneus/precuneus, as well as decreased amygdala gray matter volumes in the amygdala which is consistent with his functional MRI data suggesting increased activation in youth with anxiety disorders, relative to healthy comparison subjects, during a continuous processing task with emotional and neutral distractors. Additionally, from a neurochemistry standpoint, he has demonstrated that glutamatergic tone in the anterior cingulate cortex is directly linked with anxiety symptom severity in youth with anxiety. These studies suggest that anxiety disorders are associated with structural, functional, and neurochemical abnormalities with prefrontal-amygdala circuitry. By providing evidence of these structural, functional, and neurochemical abnormalities, this body of work has propelled additional studies of these structures in youth who are at risk for developing anxiety disorders and in studies which have allowed the integration of psychopharmacologic treatment studies with neuroimaging evaluations of anxious youth.

In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders. As an example, with his collaborators, they demonstrated the efficacy of duloxetine in a double-blind placebo-controlled trial of duloxetine which culminated in an FDA indication for duloxetine in children and adolescents with GAD (age 7-17).

Dr. Robyn Thom is a graduate of Harvard College, University of Toronto Medical School, the Harvard Longwood Psychiatry Residency Training Program, and the Massachusetts General Hospital/McLean Hospital Child and Adolescent Psychiatry Fellowship Program. As a child, adolescent, and adult psychiatrist at the MGH Lurie Center for Autism, she specializes in diagnosing and treating comorbid psychiatric conditions in individuals with autism spectrum disorder and other developmental disabilities. She has a specific interest in the psychiatric care of individuals with Williams syndrome.

Dr. Thom's research interests include psychopharmacology, anxiety disorders, Williams syndrome, medical comorbidity in adults with autism spectrum disorder, and the role of the immune system in autism spectrum disorder. She is a Harvard Medical School Dupont Warren Fellow and a recipient of the American College of Neuropsychopharmacology Travel Award.

Dr. Timothy E. Wilens is chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital (MGH), (co) director of the Center for Addiction Medicine at MGH, and the MGH Trustees Chair in Addiction Medicine. He is a professor of Psychiatry at Harvard Medical School. 

Dr. Wilens earned his BS in literature, science, and arts at the University of Michigan Honors College and his MD at the University of Michigan Medical School in Ann Arbor. His residency in child, adolescent and adult psychiatry was completed at Massachusetts General Hospital under the auspices of Harvard Medical School.  He is triple board certified in child/adolescent, adult, and addiction psychiatry. 

Dr. Wilens’ research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders; embedded health care models, and the pharmacotherapy of ADHD across the lifespan. He has published more than 300 peer-reviewed articles, concerning these and related topics, in prestigious journals such as JAMA, American Journal of Psychiatry, Archives of General Psychiatry, and Pediatrics. Dr. Wilens has also coedited/published more than 80 book chapters, 4 books, and 300 abstracts and presentations for national and international scientific meetings. 

Dr. Wilens is a distinguished fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry (AACAP), serves as the chair of new research and psychopharmacology committees for AACAP, is on the editorial boards or is a scientific reviewer for more than 35 journals, and is active in several other local and national professional societies. 

Dr. Wilens is named consistently among “The Best of Boston” in Child/Adult Psychiatry and “The Best Doctors in America.”